9M 2023 Financial Performance

9M 2023: APPENDIX Volume growth in the U.S. robust for Abilify Maintena, Rexulti and Vyepti (TRX Count) ONCE-MONTHLY 150,000 125,000 800,000 Abilify Maintena +6% +9% (aripiprazole) prolonged-release suspension for injection +8% Trintellix -2% 0% vortioxetine -6% 600,000 100,000 75,000 400,000 50,000 200,000 25,000 0 0 Q3.18 Q3.19 Q3.20 Q3.21 Q3.22 Q3.23 Q3.18 Q3.19 Q3.20 Q3.21 Q3.22 Q3.23 400,000 REXULTI 300,000 +13% +13% +7% +55% 1,000 vyepti 800 (eptinezumab-jjmr) +34% 600 200,000 400 100,000 200 0 0 Q3.18 Q3.19 Q3.20 Q2.21 Q3.22 Q3.23 Q3.20 Q3.21 Q3.22 Q3.23 32 Source: Symphony Health (ref Bloomberg). TRx is defined as Total Prescription (TRX = NRx + Refills) Lundbeck

View entire presentation